Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841301 | 0.89 | TPMT (0.65) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL1244094 | 0.89 | TPMT (0.65) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL9389844 | 0.89 | TPMT (0.65) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL18423 | 0.87 | LMNA (1.00) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL699850 | 0.87 | LMNA (1.00) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL29056089 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| Methane SCHEMBL6378712 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL7929114 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| Fluoride SCHEMBL16505425 | 0.84 | LMNA (0.94) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL9388483 | 0.82 | TPMT (0.56) | HTTLMNAMAPTESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-1926708-B1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2014-06-18 | — | — | EP | disclosed |
| US-8598359-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2013-12-03 | — | — | US | disclosed |
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
| US-5637771-A | Compound useful for lowering cholesterol | HOFFMANN-LA ROCHE INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| CN-1103781-A | Use of phenalkylamines | HOFFMANN LA ROCHE (CH) | 1995-06-21 | — | — | CN | disclosed |
| US-5286817-A | Poly(arylene sulfide)/poly(arylene sulfide sulfone) block copolymers and preparation thereof | PHILLIPS PETROLEUM COMPANY (US) | 1994-02-15 | — | — | US | disclosed |
| US-5276037-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-04 | — | — | US | disclosed |
| US-5272173-A | 5-lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| US-5225438-A | Lipoxygenase inhibitors for antiinflammatory agents or antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-07-06 | — | — | US | disclosed |
| EP-0488602-A1 | Aryl derivatives | ZENECA LIMITED (GB) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | HTT 4700/4885LMNA 2498/4885MAPT 256/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | HTT 4700/4885LMNA 2498/4885MAPT 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.